key: cord-1017309-7jkide5u authors: Lanceta, Joel; Toprak, Mesut; Rosca, Oana C. title: Merkel cell carcinoma presenting as a malignant pleural effusion post‐COVID‐19 hospitalization: A case report and literature review date: 2021-10-05 journal: Diagn Cytopathol DOI: 10.1002/dc.24882 sha: a8448a26de5ae831b57dd8ac211d90ef7d15c6cb doc_id: 1017309 cord_uid: 7jkide5u Merkel cell carcinoma (MCC) is a rare, highly aggressive neuroendocrine carcinoma of the skin, associated with immunosuppression, UV light exposure, and the Merkel cell polyomavirus (MCPyV). Cases of metastatic MCC diagnosed in body fluid cytology are extremely rare; only five cases have been reported previously in the English literature. We present a case of a 65‐year‐old male with acute respiratory failure and an enlarged right pleural effusion. He had two hospitalizations for COVID‐19 pneumonia 2 months prior, for which he received steroid treatment and tocilizumab. Emergent thoracentesis was done, with pleural fluid sent for cytologic evaluation. Both the Papanicolaou stained ThinPrep slide and cell block demonstrated clusters of predominantly small to medium sized blue round cells with hyperchromatic nuclei, scant cytoplasm and fine chromatin, in a background of rare mesothelial cells, macrophages and numerous lymphocytes. Tumor cells were positive for CD56, chromogranin, synaptophysin, SAT2B, MCPyV, and CK20 in perinuclear dot like pattern, while negative for TTF‐1 and CD45 immunostains. Ki67 proliferative index was approximately 40%. The patient had a history of MCC of the right ulnar forearm 4 years before the current presentation, which was unknown to us at the time of cytologic evaluation. To the best of our knowledge, this is the sixth case of metastatic MCC diagnosed by fluid cytology and the first reported in a patient receiving immunosuppressive treatment for COVID‐19. Further reporting of such cases may increase awareness, especially when prior history is not readily available, such as in our case. MCC is characterized by frequent recurrence, regional lymph node involvement, and distant metastases to sites like liver, lung, bone, and brain. Localized MCC disease has a 5-year survival rate of approximately 51%, which decreases to 26.8% for patients with clinically detected nodal disease, and only 13.5% for patients with distant metastatic disease. 11 Despite its increasing incidence, distant metastatic MCC involving body cavity effusions is very rare. We have identified less than 10 cases of metastatic pleural effusion MCCs in the literature, [12] [13] [14] [15] and one case of metastatic MCC in ascitic fluid. 16 [ Table 1 ]. Here, we report on a case of a 65-year-old male presenting with a right pleural effusion with a remote history of MCC, unknown to us at the time of cytologic evaluation of the effusion. To the best of our knowledge, this is the sixth case of metastatic MCC diagnosed by body fluid cytology reported in English literature, and the first one reported in a patient previously admitted for the SARS-CoV-2 virus (COVID-19). the pleura (including our case). One case was previously reported in ascites. The first case report confirmed MCC diagnosis based on electron microscopy, and was the only other case reported in a man. 15 The latter cases used IHC positivity for CK20, epithelial markers (CAM 5.2, EMA), and neuroendocrine markers (synaptophysin, chromogranin, and CD56) to confirm their diagnoses. [12] [13] [14] 16 MCPyV positivity was detected in the case of metastatic MCC in ascites. 16 Our case is unique in that we also used one of the newer neuroendocrine markers, SATB2, to confirm the diagnosis. Metastatic MCC represents a diagnostic challenge, in part to its extreme rarity in body fluid cytology. Lack of provided medical history can also contribute to MCC not being considered in the differential antibody clones. [18] [19] [20] [21] [22] Additional markers available to differentiate these tumors include CK20, which is highly sensitive and specific for MCC, as well as MCPyV and SATB2, which has recently shown to be reactive in MCC. 9,10,23 Therefore, it is essential to maintain a high index of suspicion to apply the necessary IHC panel for a diagnosis of MCC. A novel aspect to our case is the immunosuppressive treatment the patient received due to his COVID-19 hospitalizations, including tocilizumab, an interleukin-6 inhibitor, and corticosteroids. The mechanism by which immunosuppression interacts with MCPyV and/or UV radiation in MCC pathogenesis and recurrence is currently unknown. 11 MCC has been incidentally reported in patients receiving immunosuppressive treatment for rheumatoid arthritis, but clinical trials did not find a significant increased cancer risk in patients receiving tocilizumab treatment. [24] [25] [26] [27] [28] Current guidelines for COVID-19 treatment in cancer patients are the same as the general population, which recommends steroids and tocilizumab for critically acute patients. 29 To the best of our knowledge, there have been no other reported cases of de novo or recurrent malignancies in patients treated with tocilizumab for COVID-19. Further studies are warranted to delineate a possible increase in the incidence of malignant neoplasms associated with immunosuppression due to tocilizumab treatment during the pandemic. In conclusion, MCC is a highly aggressive malignancy rarely reported in body fluids. Because of its metastatic nature and rising incidence of risk factors, MCC should be included in the differential diagnosis of malignant pleural effusions, especially in cases of small blue round cell entities. The use of adequate IHC studies, like CK20 and neuroendocrine markers, including the newer SATB2 marker, can lead to an accurate diagnosis. Additional reporting of such cases may increase awareness, especially where prior history is not readily available, such as in this present instance. The authors declare no potential conflict of interest. Trabecular carcinoma of the skin Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial Angiosarcoma in collision with a Merkel cell carcinoma: case report and literature review Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system The etiology and epidemiology of Merkel cell carcinoma Merkel cell polyomavirus infection and detection Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs Clonal integration of a polyomavirus in human Merkel cell carcinoma SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas Merkel cell carcinoma: an update and review: current and future therapy A rare case of pleural localization of both metastatic Merkel cell carcinoma and chronic lymphocytic leukemia Merkel cell carcinoma metastatic to pleural fluid: a case report Merkel cell carcinoma in a malignant pleural effusion: case report Cytology of metastatic neuroendocrine (Merkel-cell) carcinoma in pleural fluid. A case report Merkel cell carcinoma presenting as malignant ascites: a case report and review of literature A comparison of the Histopathologic growth patterns between non-Merkel cell small round blue cell tumors and Merkel cell carcinoma Diffuse and strong TTF-1 positivity in a combined Merkel cell carcinoma TTF-1 positivity in Merkel cell carcinoma: the chosen clone matters Merkel cell carcinoma with cytokeratin 20-negative and thyroid transcription factor-1-positive immunostaining admixed with squamous cell carcinoma Merkel cell carcinoma concurrent with Bowen's disease: two cases, one with an unusual immunophenotype Metastatic Merkel cell carcinoma with positive expression of thyroid transcription factor-1-a case report Update on Merkel cell carcinoma Merkel cell carcinoma in a patient treated with adalimumab: case report A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab New insights and long-term safety of tocilizumab in rheumatoid arthritis Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (Accessed on How to cite this article Merkel cell carcinoma presenting as a malignant pleural effusion post-COVID-19 hospitalization: A case report and literature review All authors contributed to all aspects of writing and proofreading the manuscript. Data sharing is not applicable to this article as no new data were created or analyzed in this study. https://orcid.org/0000-0003-2243-2659